A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab with Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)

  • Arulananda, Surein (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date5/10/22 → 4/10/27